Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ARQT, unsubscribe in one click. Privacy
| PDUFA Date | Drug | Indication | Type | PoA |
|---|---|---|---|---|
| 2027-02-23 | ZORYVE cream 0.05% | infants with mild to moderate atopic dermatitis | sNDA | 89% |
PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Roflumilast FDA approved Jul 2022 · Zoryve |
Atopic Dermatitis Eczema | Phase 3 · NCT04804605 | Completed |
| Roflumilast Cream 0.15% | ITCH | Phase 4 · NCT07560618 | Recruiting |
| Topical roflumilast | Chronic Plaque Psoriasis | Phase 3 · NCT04286607 | Completed |
| Roflumilast Foam 0.3% | Seborrheic Dermatitis | Phase 3 · NCT07683806 | Recruiting |
| Roflumilast Foam | Seborrheic Dermatitis | Phase 3 · NCT04973228 | Completed |
| Roflumilast Cream 0.3% | Atopic Dermatitis | Phase 3 · NCT07916480 | Recruiting |
| Roflumilast Cream 0.05% | Atopic Dermatitis Eczema | Phase 3 · NCT04845620 | Completed |
| ARQ-151 0.3% cream | Chronic Plaque Psoriasis | Phase 3 · NCT04211389 | Completed |
| Roflumilast Cream | Atopic Dermatitis Eczema | Phase 3 · NCT04773600 | Completed |
| Roflumilast 0.3% cream | Chronic Plaque Psoriasis | Phase 3 · NCT04211363 | Completed |
| Topical roflumilast 0.3% foam | Hidradenitis Suppurativa | Phase 2 · NCT07077902 | Completed |
| Roflumilast topical 0.3% foam | Non-segmental Vitiligo | Phase 2 · NCT07105254 | Recruiting |
| ARQ-252 cream 0.3% | Vitiligo | Phase 2 · NCT04811131 | Terminated |
| ARQ-252 cream 0.1% | Chronic Hand Eczema | Phase 1/2 · NCT04378569 | Completed |
| ARQ-154 | Seborrheic Dermatitis | Phase 2 · NCT04445987 | Completed |
| ARQ-151 cream 0.5% | Psoriasis | Phase 1/2 · NCT03392168 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ARQT holds $259.5M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 8 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ARQT files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| BlackRock, Inc. | Institution (13G, 5%+) | 17,751,435 | 14.04% | 2026-09-30 |
| Montanova Capital LLC | Institution (13F) | 12,269,000 | 9.70% | 2026-09-30 |
| Frazier Life Sciences Management, L.P. | Institution (13F) | 9,874,511 | 7.81% | 2026-09-30 |
| Rubric Capital Management LP | Institution (13G, 5%+) | 8,271,577 | 6.54% | 2025-12-31 |
| STATE STREET CORPORATION | Institution (13G, 5%+) | 7,718,628 | 6.10% | 2026-09-30 |
| Polar Capital Holdings Plc | Institution (13G, 5%+) | 6,606,945 | 5.22% | 2026-06-30 |
| UBS Group AG | Institution (13F) | 5,533,053 | 4.38% | 2026-09-30 |
| Morgan Stanley | Institution (13F) | 5,296,532 | 4.19% | 2026-09-30 |
| Vanguard Capital Management LLC | Institution (13F) | 4,994,043 | 3.95% | 2026-09-30 |
| Vanguard Portfolio Management LLC | Institution (13F) | 3,817,697 | 3.02% | 2026-09-30 |
| Todd Watanabe Reporting Person's title: President and · +266,000 options |
Insider | 895,140 | 0.71% | 2026-11-02 |
| Christopher Peetz Director · +13,010 options |
Insider | 191,815 | 0.15% | 2026-07-15 |
Share count 126,455,033 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-11-04 filed 2026-11-04 |
Matsuda Masaru |
Option exercise (M) | 40,000 | $3.64 | 151,289 |
| 2026-11-04 filed 2026-11-04 |
Matsuda Masaru |
Sale (S) | 40,000 | $34.32 | 111,289 |
| 2026-11-04 filed 2026-11-04 |
Matsuda Masaru |
Option exercise (M) | 40,000 | – | – |
| 2026-11-02 filed 2026-11-04 |
Burnett Patrick |
Sale (S) | 943 | $31.86 | 116,649 |
| 2026-11-02 filed 2026-11-04 |
Watanabe Todd |
Sale (S) | 4,377 | $31.86 | 712,826 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2025-10-13 | — | sNDA | +13.3% | +3.3% | +4.1% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ARQT and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →